CytoSorbents Corporation (CTSO)

[biotech48]

that will be great getting the HemoDefend revenue, perhaps by the end of this year. I don't believe that analysts have considered it in their value of CTSO. Also, Dr. Chan stated "REFRESH 2-AKI has enrolled about 39 patients, with a target of completing the trial by 2020 and reaching FDA approval by 2021 to treat or reduce the severity of severe acute kidney injury." This is a much earlier, better and accurate timeline than others have pushed.